Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254408 | 0.92 | — | — | |
| SCHEMBL7524093 | 0.91 | GAA (0.32) | GAA | |
| SCHEMBL13592844 | 0.90 | GAA (0.30) | GAA | |
| SCHEMBL14958921 | 0.77 | GAA (0.32) | GAA | |
| SCHEMBL7248680 | 0.72 | GAA (0.33) | GAA | |
| SCHEMBL436830 | 0.72 | GAA (0.33) | GAA | |
| SCHEMBL4400772 | 0.69 | — | — | |
| SCHEMBL13613326 | 0.68 | APEX1 (0.43) | GAA | |
| SCHEMBL11768878 | 0.64 | MEN1 (0.31) | — | |
| SCHEMBL11230841 | 0.63 | GAA (0.35) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766832-B1 | Nano-enhanced explosive material | SAINT LOUIS UNIVERSITY (US) | 2020-09-08 | — | — | US | claimed |
| US-7632943-B1 | Method for making 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-dinitro-1,5-diazocine (HNFX) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-12-15 | — | — | US | claimed |
| US-10766832-B1 | Nano-enhanced explosive material | SAINT LOUIS UNIVERSITY (US) | 2020-09-08 | — | — | US | disclosed |
| US-10173945-B1 | Nanocomposite for combustion applications | nanoMetallix LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-8444783-B1 | 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-diazocinium salts | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2013-05-21 | — | — | US | disclosed |
| US-8221566-B1 | Process for employing HNFX as a biocidal explosive | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8008527-B1 | Octafluoropentaerythrityltetramine (octafluoro-peta) and process for its preparation | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2011-08-30 | — | — | US | disclosed |
| US-7632943-B1 | Method for making 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-dinitro-1,5-diazocine (HNFX) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632943-B1 | Method for making 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-dinitro-1,5-diazocine (HNFX) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632943-B1 | Method for making 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-dinitro-1,5-diazocine (HNFX) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7563889-B1 | 3,3,7,7,-tetrakis(difluoramino)octahydro-1,5-diazocinium salts and method for making the same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563889-B1 | 3,3,7,7,-tetrakis(difluoramino)octahydro-1,5-diazocinium salts and method for making the same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-07-21 | — | — | US | disclosed |
| US-6562985-B2 | Geminal-dinitro-1-5 diazocine derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2003-05-13 | — | — | US | disclosed |
| US-20020161248-A1 | Geminal-dinitro-1-5 diazocine derivatives | CHAPMAN ROBERT DALE (US) | 2002-10-31 | — | — | US | disclosed |
| US-6417355-B1 | EXPLOSIVES, PROPELLANT OXIDIZERS; FLUOROAMINATION, NITRATION, SULFONYLATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-07-09 | — | — | US | disclosed |
| US-6395899-B2 | PREPARING CYCLIC 2,2-BIS(DIFLUORAMINO)-N,N'-DINITRO-1,3-PROPANEDIAMINE VIA REACTING WITH FORMALDEHYDE OR GLYOXAL; PRODUCING 5,5-BIS(DIFLUORAMINO)HEXAHYDRO-1,3-DINITROPYRIMIDINE (RNFX); FOR EXPLOSIVES, PROPELLANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-05-28 | — | — | US | disclosed |
| US-20020007063-A1 | Preparing cyclic 2,2-bis(difluoramino)-N,N'-dinitro-1,3-propanediamine via reacting with formaldehyde or glyoxal; producing 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX); for explosives, propellants | CHAPMAN ROBERT DALE (US) | 2002-01-17 | — | — | US | disclosed |
| US-6310204-B1 | 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007063-A1 | Preparing cyclic 2,2-bis(difluoramino)-N,N'-dinitro-1,3-propanediamine via reacting with formaldehyde or glyoxal; producing 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX); for explosives, propellants | RNF5, RNF168, RBX1 | GAA 4491/4885 |
| US-20020161248-A1 | Geminal-dinitro-1-5 diazocine derivatives | TNF, TNFRSF1A, AOX1 | GAA 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.